Shares of companies developing therapies using the gene-editing technology Crispr declined Monday following the publication of research suggesting Crispr could cause far more extensive DNA damage than previously thought, leading to potentially harmful health effects for patients.
The study, published in the journal Nature Biotechnology, said the changes were often at places far away from the intentional edit, and so went undetected in previous studies, which typically observed smaller sections of genetic material. The latest...